Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Deferred Revenue: 2014-2019

Historic Current Deferred Revenue for KalVista Pharmaceuticals (KALV) over the last 4 years, with Apr 2019 value amounting to $9.5 million.

  • KalVista Pharmaceuticals' Current Deferred Revenue fell 89.09% to $1.3 million in Q1 2020 from the same period last year, while for Jan 2020 it was $1.3 million, marking a year-over-year decrease of 89.09%. This contributed to the annual value of $9.5 million for FY2019, which is 48.34% down from last year.
  • According to the latest figures from FY2019, KalVista Pharmaceuticals' Current Deferred Revenue is $9.5 million, which was down 48.34% from $18.5 million recorded in FY2018.
  • KalVista Pharmaceuticals' 5-year Current Deferred Revenue high stood at $18.5 million for FY2018, and its period low was $29,000 during FY2015.
  • Its 2-year average for Current Deferred Revenue is $14.0 million, with a median of $14.0 million in 2018.
  • Data for KalVista Pharmaceuticals' Current Deferred Revenue shows a maximum YoY tumbled of 48.34% (in 2019) over the last 5 years.
  • KalVista Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $29,000 in 2015, then reached $18.5 million in 2018, then plummeted by 48.34% to $9.5 million in 2019.